Role of Supermicrosurgical LVA for Lower Limb Lymphedema

The Role of Supermicrosurgical Lymphaticovenous Anastomosis for Lower Limb Lymphedema - A Retrospective Cohort Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04698707

Enrollment

131

Registered

2021-01-07

Start date

2020-08-28

Completion date

2020-11-19

Last updated

2021-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymphedema

Brief summary

Vascularized lymph node flap transfer (VLNT) was believed to be the treatment of choice for moderate-to-severe lymphedema. Recent publications have supported the use of supermicrosurgical lymphaticovenous anastomosis (LVA) for treating severe lymphedema. This study hypothesizes whether LVA can be performed on post-VLNT patients seeking further improvement.

Interventions

OTHERVascularized lymph node flap transfer

Patients who have received VLNT as their primary treatment but with minimal improvement

OTHERPatients without prior lymphedema surgery

Patients without prior lymphedema surgery

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 100 Years

Healthy volunteers

Inclusion criteria

* From November 2014 to January 2019 * Lower limb lymphedema patients

Exclusion criteria

* Patients who have had previous LVA, liposuction, or excisional therapy such as the Charles procedure were excluded.

Design outcomes

Primary

Measure	Time frame	Description
Magnetic resonance volumetry	6 months after LVA	Magnetic resonance volumetry was used for measuring preoperative and postoperative volume changes at least 6-month after LVA.

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026